Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

According to a recent study, roughly one in five of idiopathic pulmonary fibrosis deaths might be related to occupational exposures.

The global idiopathic pulmonary fibrosis market size was valued at USD 4.54 billion in 2024 and is projected to reach from ...

Qureight and Remedy Cell have collaborated to validate the mechanism of action of RC-0315 in the Phase Ib clinical trial for treating idiopathic pulmonary fibrosis (IPF). The trial’s primary objective ...

The following is a summary of "Supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States," published in the February 2025 issue of the Respiratory ...

Most online pulmonary rehabilitation videos are understandable but lack key disease-specific information for conditions other than COPD.

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.